SCHEMBL19002255

SCHEMBL19002255

CCC(=O)N1CCN(C(C)c2ccccc2)CC1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.74
CYP2D6 P10635 1/20 0.62
BLM P54132 1/20 0.58
MC4R P32245 1/20 0.56
CHRM1 P11229 2/20 0.54
CHRM2 P08172 1/20 0.54
CACNA2D1 P54289 4/20 0.54
CACNA1B Q00975 4/20 0.54
CACNB1 Q02641 4/20 0.54
CACNA1C Q13936 3/20 0.54
CACNA1H O95180 1/20 0.54
KDM4E B2RXH2 2/20 0.51
USP2 O75604 1/20 0.50
MAPK1 P28482 1/20 0.50
KMT2A Q03164 1/20 0.50
POLB P06746 1/20 0.50
HDAC4 P56524 1/20 0.49
HDAC1 Q13547 1/20 0.49
NPC1 O15118 1/20 0.49
TP53 P04637 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5079984 0.86 CACNA2D1 (0.73) ALDH1A1CYP2D6CACNA2D1CACNA1BCACNB1
SCHEMBL10076049 0.86 CACNA2D1 (0.72) ALDH1A1CACNA2D1CACNA1BCACNB1CACNA1C
SCHEMBL27571753 0.83 CYP2D6 (0.71) ALDH1A1CYP2D6MC4RCHRM1CHRM2
SCHEMBL19049380 0.82 KMT2A (0.73) ALDH1A1CYP2D6MC4RCHRM1CHRM2
SCHEMBL13149986 0.82 GAA (0.66) ALDH1A1CYP2D6MC4RCHRM1CHRM2
SCHEMBL21169234 0.81 CYP2D6 (0.67) ALDH1A1CYP2D6MC4RCHRM1CHRM2
SCHEMBL6706135 0.79 CYP2D6 (1.00) ALDH1A1CYP2D6MC4RCHRM1CHRM2
SCHEMBL16226061 0.79 CYP2D6 (1.00) ALDH1A1CYP2D6MC4RCHRM1CHRM2
SCHEMBL7264542 0.79 CYP2D6 (1.00) ALDH1A1CYP2D6MC4RCHRM1CHRM2
SCHEMBL28785758 0.79 BLM (0.51) ALDH1A1CYP2D6BLMCACNA2D1CACNA1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170174699-A1 COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE SHY Therapeutics LLC 2017-06-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170174699-A1 COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE MAPK6, MAP3K6, MAPK4 ALDH1A1 2765/4885CYP2D6 4551/4885BLM 3566/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.